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For over 30 years, Dyadic has proven itself, both commercially and scientifically, to be a high quality and highly 
productive producer of enzymes and proteins for specialty chemical applications using a proprietary and 
patented expression system based on the Myceliopthora thermophila fungus, nicknamed C1. 
 
The C1 platform technology, a hyper-productive fungal expression system, was used to develop & manufacture 
large quantities of desired proteins at industrial scale at significantly lower capital and operating expenditures. 
In this presentation we shall demonstrate how the benefits of C1 as a successful production host is now being 
harnessed by Dyadic to produce biological medicines and vaccines.  
 
Using new and improved C1 base strains along with better molecular genetics tools that have been developed 
over the past several years, we demonstrate the ability of C1 to express mAbs that are secreted, folded 
correctly and reach high yields. MAbs produced in C1 have almost identical binding kinetics to mAbs produced 
using CHO cells. In addition, our research program includes comprehensive approach to identify and knock-out 
proteases for further enhancing protein stability and improving yields. 
 
We have also achieved encouraging results, knowledge and experience in the rVaccine space from our prior 
research collaboration with Sanofi Pasteur to express rVaccines against Influenza virus. Results of a mice test 
that was conducted by Sanofi Pasteur, clearly demonstrated that HA produced by C1, generated high 
immunogenicity response against the virus without any adverse affects. 
 
Like other filamentous fungal strains, C1 has high mannose glycoform structures. However, unlike most fungi 
and yeasts, C1 does not have ‘high’ mannose (branched 30-50 mannose species), but rather has ‘oligo’ 
mannose structure (branched 5-9 mannose species). In addition, no O-glycosylation has been observed on C1 
secreted proteins, in contrast to Pichia that O-glycosylates all secreted antibodies, necessitating deletion of the 
O-glycosylation machinery. Using the benefits of those advantages, we have started Glycoengineering program 
aiming to develop C1 strain that produces proteins with defined human-like glycan patterns. The progress we 
have already made in C1 glycoengineering will also be presented. 
 
Thus, Dyadic firmly believe that the C1 strains that we are developing with offer certain competitive advantages 
over other leading pharmaceutical expression systems, such as CHO cells, has the potential to become the 
production system of choice for therapeutic protein and vaccines manufacturing. 
 
